ERBB3 and lung carcinoma: Recently, another study revealed that osimertinib pretreatment led to overexpression of HER3-enhanced uptake of HER3-targeted therapy with U3-1402 in lung cancer cells, suggesting the combination of osimertinib and U3-1402, with the aim to delay the development of resistance [50].